Heike I. Grabsch
A5019453132- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Gastrointestinal Tumor Research and Treatment
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Helicobacter pylori-related gastroenterology studies
- Colorectal Cancer Screening and Detection
- Colorectal and Anal Carcinomas
- AI in cancer detection
- Cancer Genomics and Diagnostics
- Colorectal Cancer Surgical Treatments
- Gastrointestinal disorders and treatments
- Lung Cancer Treatments and Mutations
- Metastasis and carcinoma case studies
- Cancer-related gene regulation
- Cancer Immunotherapy and Biomarkers
- Esophageal and GI Pathology
- HER2/EGFR in Cancer Research
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Cancer, Lipids, and Metabolism
- Microtubule and mitosis dynamics
- Diet and metabolism studies
University of Leeds
2016-2025
Maastricht University
2016-2025
Maastricht University Medical Centre
2009-2024
St James's University Hospital
2011-2024
University Medical Center
2014-2024
Leeds Teaching Hospitals NHS Trust
2003-2024
Weatherford College
2023
Metropolitan University
2020
Children's Oncology Group
2020
Cambridge University Hospitals NHS Foundation Trust
2019
Gastric cancer is a major gastrointestinal malignancy for which targeted therapies are emerging as treatment options. This study sought to identify the most prevalent molecular targets in gastric and elucidate systematic patterns of exclusivity co-occurrence among these targets, through comprehensive genomic analysis large panel cancers.Using high-resolution single nucleotide polymorphism arrays, copy number alterations were profiled 233 cancers (193 primary tumours, 40 cell lines) 98...
Many solid cancers are known to exhibit a high degree of heterogeneity in their deregulation different oncogenic pathways. We sought identify major pathways gastric cancer (GC) with significant relationships patient survival. Using gene expression signatures, we devised an silico strategy map patterns pathway activation 301 primary cancers, the second highest cause global mortality. identified three (proliferation/stem cell, NF-kappaB, and Wnt/beta-catenin) deregulated majority (>70%)...
Microsatellite instability (MSI) and mismatch-repair deficiency (dMMR) in colorectal tumors are used to select treatment for patients. Deep learning can detect MSI dMMR tumor samples on routine histology slides faster less expensively than molecular assays. However, clinical application of this technology requires high performance multisite validation, which have not yet been performed.
BackgroundPeri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric adenocarcinoma. Bevacizumab, monoclonal antibody against VEGF, improves the proportion responding to treatment in advanced gastric cancer. We aimed assess safety efficacy adding bevacizumab peri-operative gastric, junction, or lower oesophageal adenocarcinoma.MethodsIn this multicentre, randomised, open-label phase 2–3 trial, we recruited aged 18 years older histologically...
Purpose The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for patients with resectable esophagogastric cancer. However, identification at risk relapse remains challenging. We evaluated whether pathologic response lymph node status after neoadjuvant are prognostic in treated the MAGIC trial. Materials Methods Pathologic regression was assessed resection...
Background : Patients with gastric cancer (GC) have a poor survival and biologicals such as Trastuzumab not been used routinely in these patients. Existing data on HER2 expression its clinical relevance GC are still limited controversial. Methods was investigated by immunohistochemistry 418 from Germany 506 England. Results were compared to clinicopathological parameters patient survival. Less than 10% of all showed more 5% tumour cells 91% intestinal type GC. In both series, no relationship...
<h3>Objective</h3> Differences in gastric cancer (GC) clinical outcomes between patients Asian and non-Asian countries has been historically attributed to variability management. However, recent international Phase III trials suggest that even with standardised treatments, GC differ by geography. Here, we investigated gene expression differences GCs, if these molecular might influence outcome. <h3>Design</h3> We compared profiles of 1016 GCs from six three cohorts, using a two-stage...
BackgroundNeoadjuvant chemotherapy before surgery improves survival compared with alone for patients oesophageal cancer. The OE05 trial assessed whether increasing the duration and intensity of neoadjuvant further improved current standard regimen.MethodsOE05 was an open-label, phase 3, randomised clinical trial. Patients surgically resectable adenocarcinoma classified as stage cT1N1, cT2N1, cT3N0/N1, or cT4N0/N1 were recruited from 72 UK hospitals. Eligibility criteria included WHO...
Abstract Artificial intelligence (AI) can predict the presence of molecular alterations directly from routine histopathology slides. However, training robust AI systems requires large datasets for which data collection faces practical, ethical and legal obstacles. These obstacles could be overcome with swarm learning (SL), in partners jointly train models while avoiding transfer monopolistic governance. Here, we demonstrate successful use SL large, multicentric gigapixel images over 5,000...
Older and/or frail patients are underrepresented in landmark cancer trials. Tailored research is needed to address this evidence gap.
Deep learning (DL) can accelerate the prediction of prognostic biomarkers from routine pathology slides in colorectal cancer (CRC). However, current approaches rely on convolutional neural networks (CNNs) and have mostly been validated small patient cohorts. Here, we develop a new transformer-based pipeline for end-to-end biomarker by combining pre-trained transformer encoder with network patch aggregation. Our approach substantially improves performance, generalizability, data efficiency,...
Microsatellite instability (MSI)/mismatch repair deficiency (dMMR) is a key genetic feature which should be tested in every patient with colorectal cancer (CRC) according to medical guidelines. Artificial intelligence (AI) methods can detect MSI/dMMR directly routine pathology slides, but the test performance has not been systematically investigated predefined thresholds.
Deep learning (DL) can predict microsatellite instability (MSI) from routine histopathology slides of colorectal cancer (CRC). However, it is unclear whether DL also other biomarkers with high performance and predictions generalize to external patient populations. Here, we acquire CRC tissue samples two large multi-centric studies. We systematically compare six different state-of-the-art architectures pathology slides, including MSI mutations in BRAF, KRAS, NRAS, PIK3CA. Using a validation...
The proportion of epithelial and stromal cells in tumours is thought to have an important role the progression malignancy. We aimed determine whether relative tumour (PoT) was related survival colorectal cancer. PoT at luminal surface measured by point counting using virtual tissue sections a series 145 cancer cases. relationship clinicopathological parameters including cancer-specific analysed. Modified receiver operating characteristic curves were used optimum cut off points dichotomise...
In preclinical gastric cancer (GC) models, FGFR2 amplification was associated with increased tumour cell proliferation and survival, drugs targeting this pathway are now in clinical trials. FISH performed on 961 GCs from the United Kingdom, China Korea, relationship clinicopathological data overlap HER2 were analysed. The prevalence of similar between three cohorts (UK 7.4%, 4.6% Korea 4.2%), intratumoral heterogeneity observed 24% amplified cases. lymph node metastases (P<0.0001). polysomy...